The ability to design drugs (so-called 'rational drug design') has been one of the long-term objectives of chemistry for 50 years. It is an exceptionally difficult problem, and many of its parts lie outside the expertise of chemistry. The much more limited problem -how to design tight-binding ligands (rational ligand design) -would seem to be one that chemistry could solve, but has also proved remarkably recalcitrant. The question is 'Why is it so difficult?' and the answer is 'We still don't entirely know'. This perspective discusses some of the technical issues -potential functions, protein plasticity, enthalpy/entropy compensation, and others -that contribute, and suggests areas where fundamental understanding of protein-ligand interactions falls short of what is needed. It surveys recent technological developments (in particular, isothermal titration calorimetry) that will, hopefully, make now the time for serious progress in this area. It concludes with the calorimetric examination of the association of a series of systematically varied ligands with a model protein. The counterintuitive thermodynamic results observed serve to illustrate that, even in relatively simple systems, understanding protein-ligand association is challenging.
Rational ligand designMolecular recognition is, in a sense, the most important process in molecular biology. Most of the reactions and interactions that dominate the operation of living systems -recognition of sequences in nucleic acids by complementary nucleic acids and by proteins; folding of proteins; recognition of ligands by proteins; interaction of drugs and target proteins; differential stabilization of the transition state and ground state of biochemical reactions by enzymes; many others -involve molecular recognition. Understanding molecular recognition is centrally important to understanding -and controlling -the set of molecular processes that make up the cell, and life.The problem of understanding molecular recognition translates, in utilitarian terms, into being able to design ligands that bind to specific sites on biomacromolecules (most often, proteins). This problem is intellectually enormously interesting, since solving it would provide ways of modulating the activities of proteins in vivo. More practically, it is central to the idea of socalled 'rational drug design'. Generating drugs has been, and remains, a difficult, expensive, failure-prone, and highly empirical activity. The difficulty and cost of developing new drugs has become prohibitive for the pharmaceutical industry, and without improved efficiency and productivity from the R&D groups of this industry, there is a widespread concern that the rate at which new drugs will be developed in the future will be substantially less than it has been in the past. The process of generating a drug is, of course, much more complicated than simply designing a ligand that targets a protein: 'hits' and 'leads' are an important part of the process, but ADME/Tox/PK/PD (adsorption, distribution, metabolism, excre...